ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,385
-0,24%
Bitcoin
61 350,19
0,91%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Innoviva Inc (INVA)

  7. Innoviva Inc (INVA) Actualités

INVA

Innoviva (INVA)

Innoviva Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INVA
DateHeureSourceTitreSymboleSociété
08/05/202422h46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INVAInnoviva Inc
08/05/202422h44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVAInnoviva Inc
08/05/202422h05Business WireInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
08/05/202413h00Business WireInnoviva to Participate in the BofA Securities Health Care ConferenceNASDAQ:INVAInnoviva Inc
24/04/202413h00Business WireInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024NASDAQ:INVAInnoviva Inc
08/03/202401h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
29/02/202423h01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INVAInnoviva Inc
29/02/202422h05Business WireInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
14/02/202413h23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INVAInnoviva Inc
11/01/202402h26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
01/11/202321h15Business WireInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
01/11/202321h05Business WirePositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaNASDAQ:INVAInnoviva Inc
19/09/202314h30Business WireInnoviva to Participate in the Cantor Global Healthcare ConferenceNASDAQ:INVAInnoviva Inc
18/09/202314h00Business WireXACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsNASDAQ:INVAInnoviva Inc
25/08/202322h52Business WireInnoviva Appoints Stephen Basso as Chief Financial OfficerNASDAQ:INVAInnoviva Inc
02/08/202322h05Business WireInnoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
21/06/202312h03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INVAInnoviva Inc
06/06/202322h05Business WireInnoviva to Participate in the Goldman Sachs Annual Global Healthcare ConferenceNASDAQ:INVAInnoviva Inc
24/05/202312h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INVAInnoviva Inc
24/05/202301h10Dow Jones NewsFDA Approves Innoviva's Bacterial Pneumonia TreatmentNASDAQ:INVAInnoviva Inc
24/05/202300h42Business WireInnoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous UseNASDAQ:INVAInnoviva Inc
17/05/202323h19Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:INVAInnoviva Inc
15/05/202323h19Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:INVAInnoviva Inc
12/05/202300h45Business WireResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious DiseasesNASDAQ:INVAInnoviva Inc
09/05/202323h06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:INVAInnoviva Inc
09/05/202322h32Business WireInnoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
28/04/202323h30Business WireInnoviva Announces Retirement of Board ChairmanNASDAQ:INVAInnoviva Inc
28/04/202323h05Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:INVAInnoviva Inc
28/04/202323h05Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:INVAInnoviva Inc
17/04/202322h31Business WireSulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory CommitteeNASDAQ:INVAInnoviva Inc
 Showing the most relevant articles for your search:NASDAQ:INVA

Dernières Valeurs Consultées

BIT
C00166
Commerzbank
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés